TEVA PHARMACEUTICAL-SP ADR (TEVA)
US8816242098 - ADR
ChartMill assigns a Buy % Consensus number of 83% to TEVA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 0.03. This target is -99.74% below the current price.
TEVA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TEVA.
In the previous month the buy percentage consensus was at a similar level.
TEVA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-08 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-02-12 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-02-05 | Barclays | Maintains | Overweight -> Overweight |
| 2024-02-05 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-01-29 | Barclays | Maintains | Overweight -> Overweight |
| 2024-01-23 | Jefferies | Upgrade | Hold -> Buy |
| 2024-01-03 | Piper Sandler | Upgrade | Underweight -> Neutral |
| 2023-12-18 | HSBC | Initiate | Buy |
| 2023-11-27 | UBS | Upgrade | Neutral -> Buy |
| 2023-09-20 | UBS | Maintains | Neutral -> Neutral |
| 2023-09-08 | B of A Securities | Maintains | Buy -> Buy |
| 2023-07-06 | UBS | Upgrade | Sell -> Neutral |
| 2023-05-25 | Morgan Stanley | Initiate | Equal-Weight |
| 2023-05-18 | Evercore ISI Group | Upgrade | In-Line -> Outperform |
| 2023-05-11 | B of A Securities | Maintains | Buy -> Buy |
| 2023-02-09 | Barclays | Maintains | Overweight |
| 2023-01-19 | Jefferies | Downgrade | Buy -> Hold |
| 2022-11-23 | Piper Sandler | Maintains | Underweight |
| 2022-11-14 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2022-11-07 | BMO Capital | Maintains | Market Perform |
| 2022-08-05 | B of A Securities | Upgrade | Neutral -> Buy |
| 2022-08-02 | Goldman Sachs | Maintains | Neutral |
| 2022-06-14 | UBS | Initiate | Neutral |
| 2022-05-17 | B of A Securities | Upgrade | Underperform -> Neutral |
| 2022-05-12 | Goldman Sachs | Maintains | Neutral |
| 2022-05-04 | Piper Sandler | Downgrade | Neutral -> Underweight |
| 2022-02-18 | Barclays | Maintains | Equal-Weight |
| 2022-01-27 | Argus Research | Downgrade | Buy -> Hold |
| 2021-10-28 | Raymond James | Downgrade | Outperform -> Market Perform |